Advanced search
Publication Cover
Upsala Journal of Medical Sciences Volume 117, 2012 - Issue 1
Journal homepage
1,047
Views
25
CrossRef citations to date
0
Altmetric
Original Article

Substrate reduction therapy with miglustat for type 1 Gaucher disease: A retrospective analysis from a single institution

Maciej MachaczkaDivision of Hematology, Department of Medicine at Huddinge, Karolinska Institutet, and Hematology Center Karolinska, Karolinska University Hospital Huddinge, Stockholm, SwedenCorrespondence[email protected]
,
Robert HastDepartment of Medicine at Solna, Karolinska Institutet, Stockholm, Sweden
,
Ingrid Dahlman Department of Endocrinology, Karolinska University Hospital Huddinge, Stockholm, Sweden
,
Richard LernerDivision of Hematology, Department of Medicine at Huddinge, Karolinska Institutet, and Hematology Center Karolinska, Karolinska University Hospital Huddinge, Stockholm, Sweden
,
Monika KlimkowskaDepartment of Clinical Pathology and Cytology, Karolinska University Hospital Huddinge, Stockholm, Sweden
,
Martin EngvallCentre for Inherited Metabolic Diseases, Karolinska University Hospital Huddinge, Stockholm, Sweden
&
Hans HägglundDivision of Hematology, Department of Medicine at Huddinge, Karolinska Institutet, and Hematology Center Karolinska, Karolinska University Hospital Huddinge, Stockholm, Sweden
 show all
Pages 28-34 | Received 30 Aug 2011, Accepted 10 Nov 2011, Published online: 17 Jan 2012

References

  • Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 2008;29:567–83.
  • Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet. 2008;372:1263–71.
  • Mehta A. Epidemiology and natural history of Gaucher’s disease. Eur J Intern Med. 2006;17:S2–5.
  • Poll LW, Koch JA, vom Dahl S, Willers R, Scherer A, Boerner D, Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skeletal Radiol. 2001;30:496–503.
  • Rudzki Z, Okon K, Machaczka M, Rucinska M, Papla B, Skotnicki AB. Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease—a histological study. Eur J Haematol. 2003;70:273–81.
  • de Fost M, Hollak CE, Groener JE, Aerts JM, Maas M, Poll LW, Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood. 2006;108:830–5.
  • Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res. 2007;22:119–26.
  • Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000;355:1481–5.
  • Giraldo P, Alfonso P, Atutxa K, Fernández-Galán MA, Barez A, Franco R, Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project. Haematologica. 2009;94:1771–5.
  • Hollak CE, vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis. 2010;44:41–7.
  • Machaczka M, Lerner R, Klimkowska M, Hägglund H. Treatment of multiple myeloma in patients with Gaucher disease. Am J Hematol. 2009;84:694–6.
  • Pastores GM, Elstein D, Hrebicek M, Zimran A. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther. 2007;29:1645–54.
  • Mikosch P, Reed M, Baker R, Holloway B, Berger L, Mehta AB, Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat. Calcif Tissue Int. 2008;83:43–54.
  • Hollak CE, Hughes D, van Schaik IN, Schwierin B, Bembi B. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoepidemiol Drug Saf. 2009;18:770–7.
  • Champion H, Ramaswami U, Imrie J, Lachmann RH, Gallagher J, Cox TM, Dietary modifications in patients receiving miglustat. J Inherit Metab Dis. 2010 Sep 16 (Epub ahead of print).
  • Belmatoug N, Burlina A, Giraldo P, Hendriksz CJ, Kuter DJ, Mengel E, Gastrointestinal disturbances and their management in miglustat-treated patients. J Inherit Metab Dis. 2011;34:991–1001.
  • Lachmann RH, te Vruchte D, Lloyd-Evans E, Reinkensmeier G, Sillence DJ, Fernandez-Guillen L, Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. Neurobiol Dis. 2004;16:654–8.
  • Bembi B, Marchetti F, Guerci VI, Ciana G, Addobbati R, Grasso D, Substrate reduction therapy in the infantile form of Tay-Sachs disease. Neurology. 2006;66:278–80.
  • Treiber A, Morand O, Clozel M. The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica. 2007;37:298–314.
  • Cox-Brinkman J, van Breemen MJ, van Maldegem BT, Bour L, Donker WE, Hollak CE, Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III. J Inherit Metab Dis. 2008;31:745–52.
  • Chérin P, Rose C, de Roux-Serratrice C, Tardy D, Dobbelaere D, Grosbois B, The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG). J Inherit Metab Dis. 2010;33:331–8.
  • Biegstraaten M, Mengel E, Maródi L, Petakov M, Niederau C, Giraldo P, Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain. 2010;133:2909–19.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.